| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | SELL | SELL | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.92▼ | 4.83▲ | 4.82▲ | 5.18▼ | 5.34▼ |
| MA10 | 4.91▼ | 4.81▲ | 4.87▲ | 5.20▼ | 5.28▼ |
| MA20 | 4.86▲ | 4.87▲ | 4.99▼ | 5.34▼ | 4.43▲ |
| MA50 | 4.81▲ | 5.04▼ | 5.19▼ | 5.35▼ | 3.68▲ |
| MA100 | 4.86▲ | 5.20▼ | 5.12▼ | 4.38▲ | N/A |
| MA200 | 4.98▼ | 5.20▼ | 5.42▼ | 3.94▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.003▲ | 0.019▲ | 0.000▼ | -0.052▼ | -0.006▼ |
| RSI | 57.534▲ | 48.617▼ | 43.356▼ | 44.488▼ | 54.536▲ |
| STOCH | 68.097 | 50.839 | 31.339 | 48.733 | 46.990 |
| WILL %R | -37.838 | -34.483 | -54.762 | -75.072▼ | -55.457 |
| CCI | 34.277 | 107.091▲ | 24.084 | -81.739 | 10.505 |
|
Friday, August 08, 2025 03:15 AM
aTyr's lead drug, efzofitimod, just completed enrollment in its phase 3 EFZO-FIT trial for pulmonary sarcoidosis, with results expected in 2025's third quarter. Since EFZO-FIT is a single phase 3 ...
|
|
Friday, August 08, 2025 03:15 AM
aTyr's lead drug, efzofitimod, just completed enrollment in its phase 3 EFZO-FIT trial for pulmonary sarcoidosis, with results expected in 2025's third quarter. Since EFZO-FIT is a single phase 3 ...
|
|
Thursday, August 07, 2025 01:21 PM
Last patient visit completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline results expected in mid-September 2025.SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 4.95 | 4.97 | 4.715 | 4.90 | 4,226,912 |
| 14/08/25 | 5.09 | 5.14 | 4.84 | 4.99 | 3,728,436 |
| 13/08/25 | 5.20 | 5.33 | 5.0401 | 5.15 | 3,229,567 |
| 12/08/25 | 5.60 | 5.69 | 5.14 | 5.23 | 5,076,280 |
| 11/08/25 | 5.31 | 5.745 | 5.31 | 5.61 | 4,679,157 |
| 08/08/25 | 5.24 | 5.395 | 5.20 | 5.30 | 3,228,200 |
| 07/08/25 | 5.40 | 5.74 | 5.17 | 5.24 | 3,995,346 |
| 06/08/25 | 5.17 | 5.385 | 5.08 | 5.34 | 3,521,700 |
| 05/08/25 | 4.995 | 5.26 | 4.955 | 5.22 | 3,343,000 |
| 04/08/25 | 4.81 | 5.095 | 4.7535 | 5.02 | 4,114,593 |
|
|
||||
|
|
||||
|
|